Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial

por Clifford, Steven C., Lannering, Birgitta, Schwalbe, Ed C., Hicks, Debbie, O' Toole, Kieran, Nicholson, Sarah Leigh, Goschzik, Tobias, zur Mühlen, Anja, Figarella-Branger, Dominique, Doz, François, Rutkowski, Stefan, Gustafsson, Göran, Pietsch, Torsten
Publicado 2015

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

por Hill, Rebecca M., Kuijper, Sanne, Lindsey, Janet C., Petrie, Kevin, Schwalbe, Ed C., Barker, Karen, Boult, Jessica K.R., Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra L., Poon, Evon, Robinson, Simon P., Ruddle, Ruth, Raynaud, Florence I., Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah Leigh, Crosier, Stephen, Ellison, David W., Wharton, Stephen B., Robson, Keith, Michalski, Antony, Hargrave, Darren, Jacques, Thomas S., Pizer, Barry, Bailey, Simon, Swartling, Fredrik J., Weiss, William A., Chesler, Louis, Clifford, Steven C.
Publicado 2015